Vertex Pharmaceuticals Q1 2026 Earnings Call Summary
Vertex Pharmaceuticals reported strong first-quarter performance driven by non-CF products and progress in its renal franchise. The company reiterated revenue guidance of $12.95 billion to $13.10 billion for 2026, with expectations that GERNAVICS will significantly exceed prescription growth later this year.
Tickers: $VRTX
Topics: clinical trials pharmaceuticals product pipeline revenue guidance